ÂÜÀòÂÒÂ×

Alan Musso is currently the Chief Financial Officer of ReViral Ltd., a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). Prior to ReViral, Alan was the Chief Financial Officer and Treasurer at Peloton Therapeutics Inc., a company focused on the development of novel small molecule therapeutic candidates for the treatment of cancer. While at Peloton, Alan secured a $150 million mezzanine financing and prepared the company for an initial public offering until the company was acquired by Merck & Co. in July 2019. Before his tenure at Peloton, Alan served as the Chief Financial Officer and Treasurer at several biopharmaceutical companies including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals. Alan spent the early part of his career as a senior internal auditor for Pfizer as well as a Certified Public Accountant (CPA) for KPMG International.

Alan received a B.S. in Accounting from Saint Mary’s College of California, and a master’s degree from the American Graduate School of International Management.